Daily Cardiology Research Analysis
Three impactful cardiology studies stood out today. An oral PCSK9 inhibitor (enlicitide) achieved ~60% LDL-C reduction and lowered lipoprotein(a) in a phase 3 randomized trial of heterozygous familial hypercholesterolemia. A randomized trial found daily caffeinated coffee after cardioversion reduced atrial fibrillation recurrence. A large UK Biobank cohort linked non-DNMT3A clonal hematopoiesis to incident heart failure, only partly mediated by traditional comorbidities.
Summary
Three impactful cardiology studies stood out today. An oral PCSK9 inhibitor (enlicitide) achieved ~60% LDL-C reduction and lowered lipoprotein(a) in a phase 3 randomized trial of heterozygous familial hypercholesterolemia. A randomized trial found daily caffeinated coffee after cardioversion reduced atrial fibrillation recurrence. A large UK Biobank cohort linked non-DNMT3A clonal hematopoiesis to incident heart failure, only partly mediated by traditional comorbidities.
Research Themes
- Oral lipid-lowering innovation and Lp(a) modulation
- Lifestyle intervention and arrhythmia recurrence
- Genomics/inflammation linking clonal hematopoiesis to heart failure
Selected Articles
1. Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
In statin-treated adults with HeFH, the oral PCSK9 inhibitor enlicitide produced large, durable LDL-C reductions (~59% at 24 weeks; ~62% vs placebo at 52 weeks), along with significant decreases in non-HDL-C, apolipoprotein B, and lipoprotein(a). Safety and discontinuation rates were similar to placebo over 52 weeks.
Impact: This trial provides the first robust phase 3 evidence that an oral PCSK9 inhibitor can achieve LDL-C lowering comparable to injectable therapies while also reducing Lp(a), potentially transforming lipid management for HeFH.
Clinical Implications: If approved, an oral PCSK9 option could simplify access and adherence in HeFH, enabling combination therapy (with statins/ezetimibe) to reach guideline LDL-C and apoB targets; outcome trials remain necessary.
Key Findings
- At 24 weeks, LDL-C decreased by 58.2% with enlicitide vs increased 2.6% with placebo (between-group difference −59.4% [95% CI, −65.6% to −53.2%]; P<.001).
- At 52 weeks, mean LDL-C change was −55.3% with enlicitide vs +8.7% with placebo (between-group difference −61.5% [95% CI, −69.4% to −53.7%]; P<.001).
- Enlicitide reduced non-HDL-C (−52.3% vs +2.1%), apolipoprotein B (−48.2% vs +1.8%), and lipoprotein(a) median (−24.7% vs −1.6%) at week 24, all P<.001.
- Adverse events, serious adverse events, and discontinuations due to adverse events were similar between groups.
Methodological Strengths
- Multicenter, placebo-controlled randomized phase 3 design across 17 countries with high retention (96.7%).
- Prespecified lipid endpoints with consistent effects across multiple atherogenic lipoprotein measures.
Limitations
- Surrogate lipid endpoints without cardiovascular outcome data.
- Population limited to HeFH on background lipid therapy; generalizability to broader dyslipidemia populations is uncertain.
Future Directions: Conduct cardiovascular outcome trials, evaluate long-term safety and adherence, assess efficacy across non-HeFH populations and in combination regimens, and study effects on hard outcomes and Lp(a)-driven risk.
IMPORTANCE: Persons with heterozygous familial hypercholesterolemia (HeFH) are at increased risk of atherosclerotic cardiovascular disease due to lifelong elevated levels of low-density lipoprotein cholesterol (LDL-C). Many patients with HeFH do not achieve guideline-recommended LDL-C goals with the currently available lipid-lowering therapies. OBJECTIVE: To evaluate the efficacy of enlicitide decanoate (an oral proprotein convertase subtilisin/kexin type 9 inhibitor) vs placebo in adults with HeFH requiring further lowering of LDL-C levels despite use of statin therapy. DESIGN, SETTING, AND PARTICIPANTS: This phase 3, randomized clinical trial included persons aged 18 years or older with HeFH currently using lipid-lowering therapy (taking at least a moderate- or high-intensity statin) and either an LDL-C level of 55 mg/dL or greater and a history of major atherosclerotic cardiovascular disease or an LDL-C level of 70 mg/dL or greater without a history of major atherosclerotic cardiovascular disease. The trial was conducted at 59 sites across 17 countries; the first participant was screened on August 8, 2023, and the last follow-up visit occurred on April 7, 2025. INTERVENTIONS: Participants were randomized (2:1) to 20 mg of enlicitide (n = 202) or placebo (n = 101) once daily for 52 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was the mean percentage change in LDL-C level at week 24. The secondary outcomes included the mean percentage change in LDL-C level at week 52, the mean percentage change at week 24 in levels of non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B, and the median percentage change at week 24 in lipoprotein(a). RESULTS: Of the 303 participants (mean age, 52.4 [SD, 13.5] years; 51% were female) randomized, 293 (96.7%) completed the trial. The mean LDL-C level was 119.0 mg/dL (SD, 41.0 mg/dL) at baseline, all had statin current use (81.5% were taking a high-intensity statin), and 64.4% were taking ezetimibe. The mean percentage change in LDL-C level at week 24 was -58.2% in the enlicitide group vs 2.6% in the placebo group (between-group difference, -59.4% [95% CI, -65.6% to -53.2%]; P < .001). The mean percentage change in LDL-C level at week 52 was -55.3% in the enlicitide group vs 8.7% in the placebo group (between-group difference, -61.5% [95% CI, -69.4% to -53.7%]; P < .001). At week 24, the mean percentage change in non-HDL-C level was -52.3% in the enlicitide group vs 2.1% in the placebo group (between-group difference, -53.0% [95% CI, -58.5% to -47.4%]; P < .001), the mean percentage change in apolipoprotein B level was -48.2% vs 1.8%, respectively (between-group difference, -49.1% [95% CI, -54.0% to -44.3%]; P < .001), and the median percentage change in lipoprotein(a) level was -24.7% vs -1.6% (between-group difference, -27.5% [95% CI, -34.3% to -20.6%]; P < .001). The incidence of adverse events, serious adverse events, and study discontinuation due to adverse events was similar between groups. CONCLUSIONS: Among adults with HeFH, treatment with enlicitide was well tolerated and significantly reduced levels of LDL-C, apolipoprotein B, non-HDL-C, and lipoprotein(a). TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05952869.
2. Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial.
Among 200 coffee drinkers undergoing cardioversion for AF or atrial flutter, allocation to daily caffeinated coffee (median ~1 cup/day) reduced 6-month recurrence (47% vs 64%; HR 0.61, P=0.01) compared with abstinence. Adverse events did not differ between groups.
Impact: This is the first randomized trial directly testing caffeinated coffee consumption in AF patients, challenging longstanding proarrhythmic assumptions and informing practical counseling.
Clinical Implications: Routine blanket caffeine abstinence after cardioversion may be unnecessary; moderate daily caffeinated coffee appears safe and may reduce early recurrence, though confirmation in blinded, larger trials is warranted.
Key Findings
- AF/atrial flutter recurrence occurred in 47% with coffee vs 64% with abstinence over 6 months (HR 0.61, 95% CI 0.42-0.89; P=0.01).
- Between-group adherence separation was large and stable (median 7 vs 0 cups/week; difference 7 cups/week, 95% CI 7-7).
- No significant differences in adverse events between groups.
- Similar benefit was observed when analyzing AF recurrence alone.
Methodological Strengths
- Randomized design with clear adherence separation and prespecified primary endpoint.
- Multinational, multicenter trial including US, Canada, and Australia.
Limitations
- Open-label design and lifestyle intervention susceptible to expectation and co-intervention biases.
- Modest sample size and 6-month follow-up; external validity to non-drinkers or higher intake levels is uncertain.
Future Directions: Blinded, dose-ranging trials with objective caffeine biomarkers and continuous rhythm monitoring to confirm causality, define optimal intake, and explore mechanisms (e.g., autonomic modulation, adenosine receptors).
IMPORTANCE: Conventional wisdom holds that caffeinated coffee is proarrhythmic. Coffee is the most commonly consumed caffeinated beverage in the US, and a randomized trial assessing caffeinated coffee consumption in patients with atrial fibrillation (AF) has not previously been performed. OBJECTIVE: To determine the effect of caffeinated coffee consumption compared with abstinence from coffee and caffeine on recurrent AF. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective, open-label, randomized clinical trial enrolling 200 current or previous (within past 5 years) coffee-drinking adults with persistent AF, or atrial flutter with a history of AF, planned for electrical cardioversion from 5 hospitals in the US, Canada, and Australia between November 2021 and December 2024. The date of final follow-up was June 5, 2025. INTERVENTION: Patients were randomized in a 1:1 ratio to regular caffeinated coffee consumption vs coffee and caffeine abstinence for 6 months. Patients in the coffee consumption group were encouraged to drink at least 1 cup of caffeinated coffee daily. Patients in the abstinence group were encouraged to completely abstain from both caffeinated and decaffeinated coffee and other caffeine-containing products. MAIN OUTCOMES AND MEASURES: The primary end point was clinically detected recurrence of AF or atrial flutter over 6 months. RESULTS: Two hundred patients (mean [SD] age, 69 [11] years; 71% male) were randomized to caffeinated coffee consumption (n = 100) or coffee abstinence (n = 100). Baseline coffee intake was 7 cups (IQR, 7-18) per week in both groups. During follow-up, coffee intake in the consumption and abstinence groups was 7 (IQR, 6-11) and 0 (IQR, 0-2) cups per week, respectively, resulting in a between-group difference of 7 cups (95% CI, 7-7) per week. In the primary analysis, AF or atrial flutter recurrence was less in the coffee consumption (47%) than the coffee abstinence (64%) group, resulting in a 39% lower hazard of recurrence (hazard ratio, 0.61 [95% CI, 0.42-0.89]; P = .01). A comparable benefit of coffee consumption was observed with AF recurrence only. There was no significant difference in adverse events. CONCLUSIONS AND RELEVANCE: In this clinical trial of coffee drinkers after successful cardioversion, allocation to consumption of caffeinated coffee averaging 1 cup a day was associated with less recurrence of AF or atrial flutter compared with abstinence from coffee and caffeinated products. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05121519.
3. Clonal Hematopoiesis and Incident Heart Failure.
In 417,616 UK Biobank participants free of HF and major CHIP-associated comorbidities at baseline, CHIP was associated with incident HF (aHR 1.27), largely driven by non-DNMT3A subtypes (aHR 1.52). Mediation analysis indicated that intervening CAD, AF, T2D, and CKD accounted for only 28% of the non-DNMT3A CHIP–HF association.
Impact: This study refines the genetic and inflammatory underpinnings of HF by identifying specific CHIP subtypes with stronger associations and showing limited mediation by traditional comorbidities, highlighting CHIP as a novel risk factor and potential intervention target.
Clinical Implications: Incorporating CHIP status—particularly non-DNMT3A variants—into HF risk stratification may identify individuals who could benefit from targeted surveillance or anti-inflammatory/anti-clonal therapies once validated.
Key Findings
- CHIP was associated with incident HF (aHR 1.27; 95% CI 1.15-1.40).
- Non-DNMT3A CHIP subtypes (TET2, ASXL1, JAK2, spliceosome) showed stronger associations (aHR 1.52; 95% CI 1.33-1.75); DNMT3A association was modest (aHR 1.15; P=0.04).
- Mediation by subsequent CAD, AF, T2D, and CKD explained 28.2% (95% CI 11.6%-45.4%) of the non-DNMT3A CHIP–HF association.
- Over median 11.1 years, 1.7% developed incident HF among 417,616 participants.
Methodological Strengths
- Very large prospective cohort with whole-exome sequencing enabling gene-specific CHIP analyses.
- Rigorous adjustment and formal mediation analyses to explore pathways.
Limitations
- Observational design with potential residual confounding and selection bias inherent to UK Biobank.
- HF ascertainment relies on clinical coding; CHIP measured at single timepoint without clonal evolution assessment.
Future Directions: Interventional studies targeting inflammatory or clonal pathways in CHIP carriers; integrate CHIP into HF risk models; evaluate cost-effectiveness and clinical utility of CHIP screening.
IMPORTANCE: Clonal hematopoiesis of indeterminate potential (CHIP), the age-related clonal expansion of hematopoietic cells with acquired preleukemic variants, has been associated with cardiometabolic diseases, including heart failure (HF). However, prior studies have lacked power to examine less common CHIP driver variants and have not investigated potential mediators of the CHIP-HF association. OBJECTIVE: To test whether specific CHIP subtypes are associated with incident HF and determine the extent to which CHIP-associated comorbidities mediate this association. DESIGN, SETTING, AND PARTICIPANTS: This was a UK Biobank prospective population-based cohort study of community-dwelling adults in the UK, with enrollment from 2006 to 2010 and follow-up through 2020. Included were participants with whole-exome sequencing (WES) and without prevalent HF, hematologic malignancy, or other CHIP-associated comorbidities (coronary artery disease [CAD], atrial fibrillation [AF], type 2 diabetes [T2D], or chronic kidney disease [CKD]) at baseline. Study data were analyzed from April through October 2025. EXPOSURES: Presence of CHIP and gene-specific CHIP subtypes (DNMT3A, non-DNMT3A, TET2, ASXL1, JAK2, DNA damage repair genes, and spliceosome genes). Mediation analyses examined CHIP-associated comorbidities (CAD, AF, T2D, and CKD). MAIN OUTCOMES AND MEASURES: The primary outcome was incident HF. Cox regression tested associations of CHIP and CHIP subtypes with incident HF, adjusted for age, sex, race, and cardiovascular risk factors. RESULTS: Among 417 616 participants (mean [SD] age, 56.1 [8.1] years; 234 868 female [56.2%]), 7183 (1.7%) developed incident HF over a median (IQR) of 11.1 (10.4-11.8) years of follow-up. CHIP was associated with HF risk (adjusted hazard ratio [aHR], 1.27; 95% CI, 1.15-1.40; P < .001), driven by non-DNMT3A subtypes (aHR, 1.52; 95% CI, 1.33-1.75; P < .001), including associations with TET2, ASXL1, JAK2, and spliceosome CHIP. DNMT3A CHIP was more modestly associated with HF (aHR, 1.15; 95% CI, 1.00-1.31; P = .04). In mediation analyses, development of CAD, AF, T2D, and/or CKD collectively accounted for 28.2% of the association (95% CI, 11.6%-45.4%; P = .001) between non-DNMT3A CHIP and HF. CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that CHIP, especially non-DNMT3A CHIP, was associated with incident HF. Other CHIP-associated comorbidities explained only a minority of the association between non-DNMT3A CHIP and HF. These findings suggest that CHIP is an HF risk factor and potential therapeutic target.